- Home
- LYFT vs NUVL Comparison
LYFT vs NUVL Comparison
Compare LYFT & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LYFT | NUVL |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 8.1B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LYFT | NUVL |
|---|---|---|
| Price | $13.33 | $102.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 31 | 15 |
| Target Price | $20.14 | ★ $135.33 |
| AVG Volume (30 Days) | ★ 18.2M | 444.0K |
| Earning Date | 05-12-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11250.00 | N/A |
| EPS | ★ 6.81 | N/A |
| Revenue | ★ $6,316,261,000.00 | N/A |
| Revenue This Year | $17.89 | N/A |
| Revenue Next Year | $12.36 | $1,064.25 |
| P/E Ratio | $1.94 | ★ N/A |
| Revenue Growth | ★ 9.16 | N/A |
| 52 Week Low | $9.66 | $55.54 |
| 52 Week High | $25.54 | $113.02 |
Technical Indicators
Market Signals| Indicator | LYFT | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 33.97 | 49.34 |
| Support Level | $13.09 | $98.65 |
| Resistance Level | $15.27 | $107.13 |
| Average True Range (ATR) | 0.56 | 4.28 |
| MACD | 0.10 | -0.10 |
| Stochastic Oscillator | 34.35 | 52.08 |
Price Performance
Historical ComparisonAbout LYFT Lyft Inc.
Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.